Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets
2026-07-27

Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Honored with the “Green Supply Chain Leadership Award”
2026-07-17

Honored with the “Green Supply Chain Leadership Award”

Named Among “China ESG Leaders 2026”

Named Among “China ESG Leaders 2026”

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration
2026-07-15

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
2026-06-22

Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at 2026 ADA Scientific Sessions
2026-06-08

CMS’s Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at 2026 ADA Scientific Sessions

CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”
2026-05-27

CMS Wins Dual Honors at the 2026 “Golden Kunpeng”: “Best Listed Company” and “Most Investable Listed Company”

Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease
2026-05-26

Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Ulcerative Colitis and Crohn’s Disease

CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
2026-04-27

CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
2026-04-23

NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

Included in S&P Global Sustainability Yearbook (China Edition) 2026
2026-04-14

Included in S&P Global Sustainability Yearbook (China Edition) 2026

New Drug for Renal Anaemia Desidustat Tablets Approved in China
2026-03-13

New Drug for Renal Anaemia Desidustat Tablets Approved in China